Contracts for the supply of Azithromycin & Dexamethasone products pt1
key details
| Value | £305,794 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | Scotland, Wales, Northern Ireland |
| Deadline | 14 Apr 2020 |
| Contract start | 23 Apr 2020 |
| Contract end | 31 May 2020 |
| Procedure | limited |
| SME suitable | Yes |
| OCID | ocds-b5fd17-3d6de0dd-0aaa-4680-89f6-c36e64ccadcd |
Awards (5)
This procurement was awarded to 5 suppliers. Values shown are per-award; the notice total is £305,794.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Aspen Pharma Ireland Ltd shared | £305,794 | 22 Apr 2020 | active |
| Hameln Pharmaceuticals Ltd shared | £305,794 | 22 Apr 2020 | active |
| Milpharm Ltd shared | £305,794 | 22 Apr 2020 | active |
| Rosemont Pharmaceuticals shared | £305,794 | 22 Apr 2020 | active |
| Teva UK Ltd shared | £305,794 | 22 Apr 2020 | active |
description
A requirement to secure Azithromycin and Dexamethasone products for trials for Covid 19 - urgent delivery required for available stocks
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 17 Jun 2020 | Award (award) | · | 3837c09a-2e1d-4bbe-9e9f-bbd755584ce7-364803 |
more from Department of Health and Social Care
- DHSC: Fin: Interim Senior Financial Accountant · £94,250 · 29 Jul 2026
- DHSC: Fin: Interim Financial Accountant · £66,400 · 29 Jul 2026
- DHSC Sinogo claim legal support · £100,000 · 22 Jul 2026
- National Institute for Health and Care Research (NIHR) pre-action letter advice · £80,000 · 22 Jul 2026
- DHSC: ASC: Waves 3 – 5 of the Adult Social Care Workforce Employee Survey · 15 Jul 2026
- Hugh's Report - MH Impact of Life-Threatening Child Illness on Families 2026 · 26 Jun 2026
- Library Mgmt and Enquiry System, E-Archive · £22,578 · 22 Jun 2026
- DHSC: Leeds Maternity Review legal services · £432,000 · 22 Jun 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.